Immunologic Factor
Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial
Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson
Eli Lilly Expands Global Footprint with £279 Million Investment in UK’s Biotech Sector
Eli Lilly, Gateway Labs, UK biotech, life sciences, Alzheimer’s treatment, donanemab, investment, healthcare innovation
Transgene Faces Setback with Mid-Stage Failure of Cancer Vaccine Candidate
Transgene, cancer vaccine, mid-stage failure, pipeline setback, oncology research
Mirikizumab Shows Superior Histologic Response in Crohn’s Disease Compared to Ustekinumab
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease
Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results
Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody
Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development
Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.
Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research
Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy
Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)
Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment
Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition